ALIGOS
THERAPEUTICS







Lawrence M. Blatt, Ph.D.
Chairman, CEO & Co-Founder

J.P. Morgan 41st Annual Healthcare Conference
January 2023

Disclosures

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective drugs and drug candidates, the potential scope, progress, results and costs of developing our drug candidates or any other future drug candidates, the potential market size and size of the potential patient populations for our drug candidates, the timing and likelihood of success of obtaining drug approvals, ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements, plans and objectives of management for future operations, the scope of protection we are able to establish and maintain for intellectual property rights covering our drug candidates, and future results of anticipated drugs and drug candidates, and the impact of developments related to the COVID-19 pandemic and the ongoing conflict between Ukraine and Russia are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos Therapeutics in general, see Aligos' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 2, 2022, and its future periodic reports to be filed with the Securities and Exchange Commission. Except as required by law, Aligos Therapeutics undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Except where otherwise indicated, the information contained in this presentation speaks as of the date hereof or as of the date at which such information is expressed to be stated, as applicable, and such information may express preliminary estimated, unaudited results which shall be subject to audit or other year-end adjustments and such audited or adjusted results may materially differ from those contained in this presentation.

This presentation concerns drug candidates, some of which are undergoing nonclinical studies and others of which are under clinical investigation, and all of which have not yet been approved for marketing by the U.S. Food and Drug Administration. These drug candidates are currently limited by federal law to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated.

Aligos Development Portfolio
Multiple Milestones/Data Readouts Anticipated in 2023



All timelines are approximate and subject to change based on enrollment and operational considerations. Presentations at conferences are subject to abstract approvals.

ALIGOS THERAPEUTICS

AASLD = American Association for the Study of Liver Diseases; APASL = Asian Pacific Association for the Study of the Liver; CAM-E = capsid assembly modulator (empty); CHB = chronic hepatitis B; Covid-19 = coronavirus disease of 2019 (SARS-CoV-2); CTA = clinical trial application; EASL = European Association for the Study of the Liver; GLP = good laboratory practice; HV = healthy volunteers; MAD = multiple ascending doses; MOA = mechanism of action; NASH = nonalcoholic steatohepatitis; PK = Pharmacokinetics; SAD = single ascending doses; siRNA = small interfering ribonucleic acid (RNAi); THR-β = thyroid hormone receptor beta.

ALIGOS
THERAPEUTICS

NASH

ALG-055009, small molecule THR-β agonist



ALG-055009
More Potent and Selective In Vitro than MGL-3196 and VK-2809

Relative THR-α and THR-β Activity in Cell-Based Assays

	EC_{50} α (nM)	EC_{50} β (nM)	Relative THR-β Selectivity (α/β)
T3	14.2	11.6	1.2
MGL-3196	5927	2366	2.5
VK-2809 parent	366	269	1.4
ALG-055009	**191**	**50**	**3.8**

In vitro, ALG-055009 is 5-47x more potent compared to resmetirom (MGL-3196) and 2-3x more selective for THR-β than VK-2809*

High β selectivity and potency may improve risk-benefit profile

ALIGOS THERAPEUTICS

*Data collected in HEK293T cells.

ALG-055009
Best In Class Potential vs. 1st Generation THR-β Agonists

Parameter		VK-2809	Resmetirom	ALG-055009
Efficacy	28 day mouse DIO TC, LDL lowering	28%	28%	Up to 44%
	Percent of patients with ≥30% change from baseline in MRI-PDFF (Ph2)	76%-100%	60%	High Expected
	BCRP, OATP substrate	?	Yes	No (NTCP)
	AUC/Cmax interindividual variability	Limited	High	Low
	PK linearity	Yes	No	Yes
Safety	β Selectivity (α/β)*	1.4	2.5	3.8
	Potential cardiosafety (i.e., α) liability	Yes	No	No
	Reactive metabolites in vitro* (GSH adduct) / Risk for DILI	Yes	No	No
	Possible Prodrug liability	Yes**	No	No
DDI	CYP inhibition >50% @10 µM*	>60% for 5 isozymes >90% for 2C9 & 2C19 CYP3A4-dependent activation	91% for 2C8	No

Potential for enhanced efficacy/PK vs. resmetirom and enhanced efficacy/safety vs. VK-2809

ALIGOS THERAPEUTICS

Abbreviations: AUC = area under the curve, BRCP = breast cancer resistance protein, Cmax = maximum concentration, CYP = cytochrome P450, DILI = drug induced liver injury, DIO = diet induced obesity; GSH = glutathione, LDL = low density lipoprotein, MRI-PDFF = magnetic resonance imaging – proton density fat fraction; OATP = organic anion transporting polypeptide, TC = total cholesterol,
* ALG-055009 clinical data from Charfi et al., EASL 2022. Competitor data derived from in-house studies.
**Same pro-drug as Pradefovir (pro-drugged adefovir). Pradefovir, but not adefovir, found carcinogenic in mice and rats (http://media.corporate-ir.net/media_files/IROL/89/89839/PipelineAug07.pdf).

Study ALG-055009-301
Single Ascending Dose (SAD) PK, Safety Data

- Oral doses evaluated: 0.1, 0.3, 0.9, 2.6, 4.0 mg
- PK
  - Dose proportional, with low variability
  - $t_{1/2}$ = 20-24 hours (supports once daily (QD) dosing)
- Safety: well tolerated
  - No serious adverse events (SAEs), premature discontinuations, Grade ≥3 treatment emergent adverse events (TEAEs), or clinical hyper/hypothyroidism



Single (≤ 4 mg) ALG-055009 doses well tolerated with favorable PK properties

ALIGOS THERAPEUTICS

Charfi et al., EASL 2022.

Study ALG-055009-301
SAD Biomarker Data

- Expected dose related thyromimetic effects observed
  - Increases in Sex Hormone Binding Globulin (SHBG; target engagement)
  - Decreases in lipids
    - Triglycerides (TG), LDL, Apolipoprotein-B (Apo-B)
  - Decreases in thyroid hormones
    - Thyrotropin (TSH), T3, T4

Expected thyromimetic effects observed, including evidence of anti-lipid activity

ALIGOS THERAPEUTICS

Charfi et al., EASL 2022.

Study ALG-055009-301
Multiple Ascending Dose (MAD) PK, Safety Data

- Oral doses evaluated: 0.3, 0.5, 0.6, and 1.0 mg QD x 14 days
- PK: favorable profile (dose-proportional, low variability (≤27%), 2x accumulation)
- Safety: well tolerated, no clinical evidence of hypo or hyperthyroidism
  - No SAEs, discontinuations
  - All TEAEs Grade ≤2
  - No concerning labs, ECGs, vital signs, physical examinations



Multiple doses (≤1 mg) well tolerated with favorable PK

ALIGOS THERAPEUTICS

Study ALG-055009-301
MAD Biomarkers – SHBG



Dose proportional increases in SHBG

ALIGOS THERAPEUTICS

Charfi et al., AASLD 2022.

Study ALG-055009-301
MAD Biomarkers - Lipids



Dose responsive reductions in LDL cholesterol
Similar pattern observed for Apo-B, Triglycerides

ALIGOS THERAPEUTICS

Charfi et al., AASLD 2022.

Study ALG-055009-301
MAD Biomarkers – Thyroid Hormones



Dose responsive reduction in free T4
Up to ~20% declines (while remaining in normal range) for doses ≤0.6 mg
Greater declines for 1 mg dose
Similar pattern observed for other thyroid hormones

ALIGOS THERAPEUTICS

Charfi et al., AASLD 2022.

Study ALG-055009-301
Summary of Phase 1 Data

- PK demonstrates a favorable profile that is differentiated vs. resmetirom
- Safety – well tolerated without clinical safety signals
- PD – generally dose proportional
  - Increases in SHBG
  - Decreases in thyroid hormones
  - Decreases in LDL, triglycerides, Apo-B

Anti-lipid effects for 0.5-1 mg ALG-055009 similar to resmetirom
ALG-055009 doses in the 0.3 to <1 mg range well suited for advancement into Phase 2

ALIGOS THERAPEUTICS

ALG-055009
Favorably Differentiated from Resmetirom

- More uniform exposure may lead to more consistent efficacy and safety across patient populations

- Low risk of drug-drug interactions in a NASH population which often requires polypharmacy
  - ALG-055009 shows no inhibition of any cytochrome P450 or transporters at clinically relevant exposures

- Greater potency leads to similar anti-lipid activity at >80-fold lower doses

Charfi et al., AASLD 2022.

ALG-055009
Next Steps

Complete Last Cohort of Phase 1
(Relative Bioavailability/Food Effect Study)

Phase 2 CTA

13 Week GLP Toxicology Studies

Phase 2 Drug Supply

Q1 | Q2 | Q3 | Q4

2023

On track to complete Phase 2 enabling activities and file Phase 2 CTA in Q4 2023

ALIGOS THERAPEUTICS

ALIGOS
THERAPEUTICS

Coronavirus

- ALG-097558 (CoV Protease Inhibitor)



ALG-097558
Aligos' Potent COVID-19 Protease Inhibitor

- Despite the availability of prophylactic vaccines, a need for therapeutics still exists
  - New variants are continuously emerging
  - Large segments of global population lack access to, or are opposed to, vaccination
  - Especially needed to prevent hospitalization in high-risk groups where standard of care is contraindicated

- Current therapeutics lack sufficient efficacy (molnupiravir, Merck), require ritonavir boosting (nirmatrelvir, Pfizer) or are delivered parenterally (remdesivir, Gilead; mAbs)

- In collaboration with KU Leuven/Rega Institute/CD3, we have identified ALG-097558
  - 7-27 times more potent than nirmatrelvir in both biochemical and cell-based assays
  - Can be dosed orally without the need for ritonavir
  - Broadly active against a diverse range of coronaviruses with a high barrier to resistance
  - Can be combined to prevent emergence of resistance and provide broader strain coverage

ALG-097558 is a potent pan-coronavirus protease inhibitor that does not require ritonavir boosting

ALIGOS THERAPEUTICS

ALG-097558
Superior Biochemical Potency Against SARS-CoV-2

SARS-CoV-2 3CLpro	IC_{50} (nM)[1]	Hillslope	K_i (nM)
PF-07321332	2.92	0.91	2.03
PBI-0451	3.6	1.74	3.4
S-217622	4.0	1.31	2.6
ALG-097558	**0.26**	**1.99[2]**	**0.074**

ALG-097558 K_i is 27-46 fold more potent vs. competitors in the 3CLpro biochemical assay

ALIGOS THERAPEUTICS

[1]The assays were performed with 0.3 nM 3CLpro.
[2]High hillslope (>1.5) is indicative of enzyme titration.

ALG-097558
Superior Cell-Based Potency Against SARS-CoV-2 and Variants

	Virus	Variant/Cell line	EC_{50} (μM)			
			Pardes PBI-0451	Shionogi S-217622	Pfizer PF-07321332	Aligos ALG-097558
Beta	SARS-CoV-2	03021/2020 Vero E6+CP	n.d.	n.d.	0.116	0.010
Beta	SARS-CoV-2	B.1.1.7 (alpha) A549-ACE2-TMPRSS2	0.038	0.023	0.099	0.012
Beta	SARS-CoV-2	B.1.617.2 (delta) A549-ACE2-TMPRSS2	0.126	0.141	0.217	0.013
Beta	SARS-CoV-2	B.1.1.529 (omicron) VeroE6-GFP+CP	0.136	0.095	0.059	0.008
Beta	SARS-CoV-1	Vero-E6+CP	0.323	0.154	0.173	0.022
Beta	OC43 (β-hCoV)	HeLa EC_{50}	0.168	n.d.	0.047	0.009
Alpha	229E (α-hCoV)	Huh-7 EC_{50}	0.281	6.30	0.476	0.017

ALG-097558 demonstrates pan-coronavirus antiviral activity
ALG-097558 is more active than PF-07321332, PBI-0451 and S-217622 across all CoV's tested
At least 7-fold more active than competitors against SARS-CoV-2 Omicron variant

ALIGOS THERAPEUTICS

Aligos data.

ALG-097558
Oral Therapeutic Treatment in the SARS-CoV-2 Hamster Model

Amount of Infectious Virus on Day 4



Significant reduction in infectious virus titers after therapeutic treatment with ALG-097558
Use of ritonavir is only needed in the hamster model

ALIGOS THERAPEUTICS | KU LEUVEN | CD3 CENTRE FOR DRUG DESIGN AND DISCOVERY

5 Hamsters / group, intranasal infection, B.1.617.2 (1 x 10^4 $TCID_{50}$).
Treatment started before or after infection as indicated, administered by oral gavage BID over 3-days.
RTV administered 1 h before the ALG cpd, RTV and ALG-097558 formulated as a solution in 43% Ethanol + 27% PG in water.
Sacrifice and assessment of infectious virus in lung at day 4.

ALG-097558
SARS-CoV-2 3CLpro L50F E166A L167F Mutant

- ALG-097558 has the least loss of activity against a triple mutant conferring resistance to other SARS-CoV-2 PIs

Compound Name	Biochemical	VeroE6+CP
	L50F/E166A/L167F (fold change versus WT)	L50F/E166A/L167F EC_{50} [μM] (fold change)
PF-07321332 (Pfizer)	66 (n=6)	3.5-3.7 (38-fold)
PBI-0451 (Pardes)	>65 (n=2)	7.6-8.4 (25-fold)
S-217622 (Shionogi)	>67 (n=2)	15-16 (59-fold)
ALG-097558 (Aligos)	3 (n=3)	0.11-0.14 (9-fold)

Potential for ALG-097558 to retain significant potency against resistant mutants

ALIGOS THERAPEUTICS KU LEUVEN CD3 CENTRE FOR DRUG DESIGN AND DISCOVERY

ALG-097558
Coronavirus Protease Inhibitor Drug Candidate

- Potent pan-coronavirus protease inhibitor drug candidate
  - Additional candidates from the series advancing as backup compounds
- Superior preclinical profile versus PF-07321332 (Pfizer)
  - 7-27 fold more potent in biochemical and cell-based assays vs. SARS-CoV-2
    - 7-fold more potent vs. the omicron variant (cell-based assay)
  - Greater cellular potency across other coronavirus strains
  - Retains activity against resistant variants
  - Excellent efficacy in the SARS-CoV-2 hamster model
- Potential for more convenient, less complex treatment regimen
  - PK profile in preclinical species predicts a projected human efficacious dose of 350-600 mg BID without ritonavir
- Timelines: Phase 1 enabling activities ongoing, HV dosing starts H1 2023

ALG-097558 is a ritonavir-free, highly differentiated, pan-coronavirus protease inhibitor

ALIGOS THERAPEUTICS

ALIGOS
THERAPEUTICS

Chronic Hepatitis B



Therapeutic Approaches to CHB Functional Cure

Inhibit Viral Replication	Lower Antigen Burden	Boost Immune Response



ALIGOS
THERAPEUTICS

Inhibiting Viral Replication

- ALG-000184 (CAM-E)



ALG-000184
Phase 1 Study in CHB Subjects

Multiple Doses in Currently Not Treated/Treatment Naïve CHB Subjects

HBV DNA > 2000 IU/mL, HBeAg- or HBeAg+
Up to 6 cohorts (n=10 per Cohort, n=8 ALG-000184, n=2 Placebo)
28 daily oral doses
Endpoints: PK, safety, antiviral activity (e.g., DNA, RNA)



Parts 1-2 (complete): SAD/MAD in HV – good safety, PK
Part 3: ALG-000184 mono-rx for 28 days in HBeAg- (100, 50, 10 mg) or HBeAg+ (100, 300, 10 mg) – good safety, PK

ALIGOS THERAPEUTICS

All cohorts complete except 10 mg in HBeAg+ (dosing).
Gane et al., APASL 2021; Gane er al., HBV-TAG 2021; Yuen et al., Poster #SAT-145 EASL 2022; Hou et al., Poster #1329, AASLD 2022.
clinicaltrials.gov: NCT04485663.

ALG-000184-201
Part 3 Cohorts 1-5 Antiviral Activity – HBV DNA and HBV RNA

Mean (SEM) Serum HBV DNA and HBV RNA Levels Change from Baseline Through the End of Study





HBeAg- CHB subjects:	Similar HBV DNA reduction for 10, 50 and 100 mg (~3-4 log_{10} IU/mL) DNA, RNA <LLOQ in ≥75% and 100% of subjects, respectively
HBeAg+ CHB subjects:	Potent DNA, RNA reductions observed (100 and 300 mg)

ALIGOS THERAPEUTICS

*Roche Cobas® HBV DNA (LLOQ = 10 IU/mL).
**Roche Cobas® assay. The HBV RNA Investigational assay is not approved in any market (LLOQ =10 copies/mL).
Yuen et al., Poster #SAT-145 EASL 2022; Hou et al., Poster #1329, AASLD 2022.

ALG-000184
Antiviral Activity vs. Competitor CAM-Es (HBeAg Negative)

Drug Name	Current Status	Dose	HBV DNA	
			Mean Decline from BL to EOT (Log_{10} IU/mL)	% < LLOQ at Day 28
ALG-000184	**Phase 1**	**10 mg**	**3.7**	**100**
EDP-514[5,**]	Phase 1b	200 mg	2.9	N/A
		800 mg	3.4	N/A
Vebicorvir[1,2]	Discontinued	300 mg	2.5	25
JNJ-6379[3,4,*]	Discontinued	250 mg	2.7	56
AB-836[6]	Discontinued	100 mg	3.1	N/A

10 mg ALG-000184 has more potent antiviral activity than competitor CAM-Es dosed at 100-800 mg

ALIGOS THERAPEUTICS

*89% of subjects were HBeAg negative in 250 mg JNJ-6379 arm. **An unknown percentage of subjects dosed with 800 mg EDP-514 were HBeAg negative. N/A – not available; LLOQ (DNA) was ≤20 IU/mL for ABI and JNJ and 10 IU/mL for Aligos.

1. MF Yuen et al. Lancet Gastroenterol Hepatol 2019; 2. MF Yuen AASLD 2018; 3. Zoulim F., et al AASLD 2018; 4. Zoulim F., et al. Gastroenterology 2020; 5. MF Yuen, et al AASLD 2021 (Poster 823). 6. HEP Dart 2021 (preliminary data).

ALG-000184
HBsAg Reductions Observed in 28-Day Monotherapy



Max HBsAg reduction: 0.52 log_{10} IU/mL | 0.23 log_{10} IU/mL | 0.35 log_{10} IU/mL | 0.78 log_{10} IU/mL | 0.50 log_{10} IU/mL

28-day monotherapy at 100 and 300 mg PO QD results in 0.2-0.8 log_{10} IU/mL HBsAg decline in 5 subjects
Best in class activity – no other CAM-E has reported same extent of HBsAg reductions in 28 days
Longer duration cohorts (± entecavir) are currently being enrolled/dosed in Part 4

ALIGOS THERAPEUTICS

Hou et al., Poster #1329, AASLD 2022.
NCT04536337.

ALG-000184-201
Part 4 Study Design – up to 48 Weeks of Dosing



ALIGOS THERAPEUTICS

Available preliminary safety, PK, and antiviral activity data as of 23 Dec 2022 are presented.
ETV = entecavir.

ALG-000184-201 (Part 4)
ALG-000184 + ETV Lowers DNA/RNA More Than ETV Alone





Reduction at Week 10	Placebo + ETV, N=3	ALG-000184 100 mg + ETV, N=7	ALG-000184 300 mg + ETV, N=6
HBV DNA, mean (SEM) log_{10} IU/mL	-3.7 (0.43)	-4.9 (0.28)	-5.2 (0.3)
HBV RNA, mean (SEM) log_{10} copies/mL	0.08 (0.05)	-2.7 (0.21)	-3.3 (0.29)

ALIGOS THERAPEUTICS

Data on file.

ALG-000184-201 (Part 4)
300 mg ALG-000184 + ETV Lowers HBsAg Over Time





Clear downward trend over 10 weeks for HBsAg among majority of 300 mg ALG-000184 treated subjects

ALIGOS THERAPEUTICS

Data on file.

ALG-000184-201
Ongoing Phase 1b Cohorts

- Enrollment/dosing in multiple longer duration (≤48 weeks) cohorts is ongoing
- Cohorts designed to address several key questions, including
  - Impact of treatment with/without entecavir
  - Antiviral activity in different patient populations (high/normal baseline ALT, HBeAg positive or negative)
- Available cohort data to be presented at APASL, EASL, and AASLD in 2023

Longer dosing duration (≤48 weeks) cohorts currently being enrolled and dosed
Data will be presented at scientific conferences throughout 2023

ALIGOS THERAPEUTICS

ALIGOS
THERAPEUTICS

Lowering S-Antigen Burden

- ALG-125755 (siRNA)



Short Interfering Nucleic Acid ALG-125755
Discovery and Advancement of a Differentiated siRNA

- siRNAs have demonstrated clinical validation in CHB infected patients

- We have designed our siRNA sequences using our proprietary technology and liver targeting conjugation to maximize in vitro and in vivo potency
  - Proprietary patterns discovered to increase potency and stability/duration of action
  - Exclusive license to GalNAc technology applicable for liver targeting across oligo modalities

- Our siRNA approach may have safety, stability and potency advantages vs. competitor siRNAs

Aligos oligonucleotide know-how and proprietary technologies have resulted in a differentiated siRNA

ALIGOS THERAPEUTICS

ALG-125755
Repeat Dosing in the AAV-HBV Mouse Model vs. VIR-2218

VIR-2218*



ALG-125755



ALG-125755 demonstrates a more sustained reduction in HBsAg vs. competitor siRNAs

ALIGOS THERAPEUTICS

*Data from Anglero-Rodriguez Y. et al., "In Vitro and In Vivo Characterization of VIR-2218, an Investigational RNAi Therapeutic Targeting Hepatitis B Virus." EASL 2020, Poster SAT426.

ALG-125755-501
Study Timelines



SAD in HV: Part 1 Cohorts 1-4 (20 mg, 60 mg, 100 mg and 200 mg) completed dosing
SAD in CHB: Part 2 Cohort 1 enrollment completed (50 mg)

ALIGOS THERAPEUTICS

Clinical Experience with siRNAs
HBsAg Reduction After 28 Days in CHB Patients



Consistent reductions of ~0.5 log_{10} IU/mL noted for competitor siRNAs 28 days after a single dose

ALIGOS THERAPEUTICS

Data derived from multiple studies: VIR-2218, Yuen et al., AASLD 2022; AB-729, Yuen et al., AASLD 2020; RG6346, Yuen et al., AASLD 2020; JNJ-3989, Yuen et al., AASLD 2021.

ALIGOS
THERAPEUTICS

Boosting the Immune Response

- Liver Targeted Oral PD-L1 Inhibitor (Small Molecule)



PD-L1 Inhibitors

- Exhaustion of HBV specific T-cells contributes to the persistence of CHB
- Proof of concept in CHB with anti-PD1 antibodies has been established
  - Multiple clinical studies have demonstrated HBsAg reductions in CHB infected patients
- Aligos has discovered several potent series of small molecule PD-L1 inhibitors
  - Potential for oral delivery and targeting to the liver
    - Liver targeting may avoid the safety liabilities seen with parenterally delivered anti-PD1 antibodies while improving efficacy
- Lead compound is a novel liver-targeted small molecule PD-L1 inhibitor
  - Biochemical and cell-based potency established
  - Activation of HBV specific T-cells demonstrated with similar potency as durvalumab
  - Liver targeting achieved with lead compound

ALIGOS THERAPEUTICS

Gane et. al, Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study. J Hepatol. 2019 Nov;71(5):900-907.

Aligos CHB Portfolio Consists of the Key Pillars Which are Likely Necessary for Enhanced Functional Cure Rates

Replication Inhibition		HBsAg Reduction		Immune Stimulation
CAM-E Inhibitor **ALG-000184**	+	siRNA **ALG-125755**	+	PD–L1 inhibitor oral small molecule

ALIGOS THERAPEUTICS

Aligos Therapeutics is Advancing Multiple Drug Candidates in the Clinic

- NASH
  - THR-β agonist (ALG-055009) – more uniform exposure may lead to more consistent efficacy and safety across patient populations
  - Merck collaborations are progressing
- Coronavirus Protease Inhibitor (ALG-097558)
  - On track to complete FIH enabling nonclinical studies and dose in Phase 1 in H1 2023
- CHB – 3 MOAs which, when combined, may increase functional cure rates
  - CAM-E (ALG-000184) - best in class HBsAg, DNA, RNA data. Ph1b (≤48 weeks) ongoing
  - siRNA (ALG-125755) is differentiated in AAV-HBV, dosing in CHB ongoing
  - PD-L1 liver-targeted, small molecule - advancing towards candidate selection
- As of September 30, 2022; cash balance was $142.3M*; fully diluted common shares: 52,897,859

ALIGOS THERAPEUTICS

*Reflects unrestricted cash, cash equivalents and investments.


ALIGOS
THERAPEUTICS